De Giglio, A.; Aprile, M.; Di Federico, A.; Sperandi, F.; Melotti, B.; Gelsomino, F.; Ardizzoni, A.
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). Int. J. Mol. Sci. 2022, 23, 10292.
https://doi.org/10.3390/ijms231810292
AMA Style
De Giglio A, Aprile M, Di Federico A, Sperandi F, Melotti B, Gelsomino F, Ardizzoni A.
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences. 2022; 23(18):10292.
https://doi.org/10.3390/ijms231810292
Chicago/Turabian Style
De Giglio, Andrea, Marta Aprile, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino, and Andrea Ardizzoni.
2022. "Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)" International Journal of Molecular Sciences 23, no. 18: 10292.
https://doi.org/10.3390/ijms231810292
APA Style
De Giglio, A., Aprile, M., Di Federico, A., Sperandi, F., Melotti, B., Gelsomino, F., & Ardizzoni, A.
(2022). Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal of Molecular Sciences, 23(18), 10292.
https://doi.org/10.3390/ijms231810292
